Anzalone and colleagues introduced prime editing, a system designed to write specified substitutions, small insertions or deletions without requiring a full double-strand DNA break.
The method expands the set of edits that can be attempted in cells, but efficiency varies with sequence context and delivery. Unintended edits, cellular responses and reproducibility still require careful measurement.
A compelling molecular tool is not the same as an approved therapy. Translating editing systems requires disease-specific evidence, manufacturing controls, safety studies and regulatory review.
STKEY note: editorial summary; consult the original paper for the complete protocol and data.